A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation

The rationale for the current protocol is to collect data from extended follow up in subjects
that have received a kidney transplant following imlifidase dosing to provide a better
understanding regarding the long-term outcome for these subjects. Data of parameters such as
patient and graft survival, comorbidity, treatment of rebound of DSAs and quality of life as
well as anti-drug antibody levels will be collected.

This prospective, observational follow up study of subjects who have received imlifidase
prior to kidney transplantation will provide important data to future prescribers and
patients of the potential long-term benefits of imlifidase mediated transplantation.